Clinical trial
Dose-ranging Study to Evaluate the Safety & Immunogenicity of a HIV Vaccine…
NCT00434512 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00434512 |
|---|---|
| Title | Dose-ranging Study to Evaluate the Safety & Immunogenicity of a HIV Vaccine 732461 in Healthy HIV Seronegative Volunteers |
| Official title | A Dose-ranging Study to Compare the Safety and Immunogenicity of a Candidate Human Deficiency Virus (HIV) Vaccine 732461, Adjuvanted or Not, Administered According to a 0, 1 Month Schedule to Healthy Adult HIV Seronegative Volunteers. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | AIDS, HIV Infections |
| Intervention type | Biological |
| Interventions | HIV vaccine 732461 |
| Enrollment | 180 |
| Start date | Feb 20, 2007 |
| Primary completion | Jun 13, 2008 |
| Completion | Jun 13, 2008 |
| First posted | Feb 13, 2007 |
| Last update posted | Oct 1, 2019 |
| Countries | Belgium |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: